Brookline Capital Management Reaffirms “Hold” Rating for Eyenovia (NASDAQ:EYEN)

Eyenovia (NASDAQ:EYEN)‘s stock had its “hold” rating reaffirmed by equities research analysts at Brookline Capital Management in a research report issued on Friday,Benzinga reports.

EYEN has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a report on Wednesday. William Blair reissued a “market perform” rating on shares of Eyenovia in a report on Friday.

Eyenovia Trading Down 70.0 %

Shares of EYEN stock opened at $0.10 on Friday. The stock has a market capitalization of $6.53 million, a price-to-earnings ratio of -0.14 and a beta of 1.75. The company’s fifty day simple moving average is $0.49 and its two-hundred day simple moving average is $0.71. Eyenovia has a 1 year low of $0.09 and a 1 year high of $2.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter last year, the business posted ($0.18) EPS. As a group, analysts anticipate that Eyenovia will post -0.56 earnings per share for the current year.

Insider Activity

In other news, CEO Michael M. Rowe acquired 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were bought at an average cost of $0.57 per share, with a total value of $28,500.00. Following the acquisition, the chief executive officer now owns 82,927 shares in the company, valued at approximately $47,268.39. This represents a 151.85 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Eyenovia

Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its position in Eyenovia by 1,444.4% during the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after acquiring an additional 205,390 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eyenovia by 25.2% during the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after purchasing an additional 360,924 shares during the period. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares during the period. Ground Swell Capital LLC purchased a new position in Eyenovia during the 2nd quarter valued at about $27,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Eyenovia during the 2nd quarter valued at approximately $26,000. 25.84% of the stock is currently owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.